Table 1.
Therapeutic targets and medication related to type 2 inflammation in BP.
| Medication | Therapeutic target | Research status | |
|---|---|---|---|
| In BP | In other type 2 inflammatory diseases | ||
| Dupilumab | IL-4R | Phase 2/3 clinical trial | Approved for AD |
| Mepolizumab | IL-5 | Phase 2 clinical trial | Using in therapy of eosinophilic granulomatosis with polyangiitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps |
| Reslizumab | IL-5 | A case report showed its therapeutic effects | Approved for eosinophilic asthma |
| Benralizumab | IL-5R | / | Using in therapy of eosinophilic granulomatosis with polyangiitis and in the prevention of chronic obstructive pulmonary disease exacerbations |
| Tralokinumab | IL-13 | / | Approved for moderate-to-severe AD |
| Lebrikizumab | IL-13 | / | Using in therapy of asthma and AD |
| Bertilimumab | Eotaxin-1 | Phase 2 clinical trial | / |
| AKST4290 | CCR3 | Phase 2 clinical trial | / |
| Nemolizumab | IL-31RA | / | Using in therapy of AD and prurigo nodularis |
| Omalizumab | IgE | Phase 3 clinical trial | Approved for severe persistent asthma and chronic idiopathic or spontaneous urticaria |
| Ligelizumab | IgE | Phase 2 clinical trial | Using in therapy of chronic spontaneous urticaria |
| Tezepelumab | TSLP | / | Using in therapy of asthma |